LENZ Therapeutics (LENZ) Q3 2024 earnings summary

Executive summary

• NDA for LNZ100, a once-daily aceclidine-based eye drop for presbyopia, accepted by FDA with a PDUFA target action date of August 8, 2025; commercial launch preparations underway for Q4 2025.

• LNZ100 demonstrated strong Phase 3 efficacy and safety, with 71–74% of participants achieving ≥3-line near vision improvement at 3 hours and robust results in both US and China trials.

• Surveys show 75% of patients intend to continue use and 82% of US eye care professionals likely to prescribe LNZ100.

• Transitioned from late-stage clinical development to a pre-commercial company, focusing on US launch and commercial infrastructure buildout.

• Completed a reverse merger with Graphite Bio in March 2024 and raised $83.5M in Series B, $53.5M in March PIPE, and $30M in July PIPE.

Financial highlights

• Ended Q3 2024 with $217.2 million in cash, cash equivalents, and marketable securities, expected to fund operations through post-launch positive cash flow.

• Q3 2024 net loss was $10.2 million ($0.38 per share), down from $18.9 million ($9.62 per share) in Q3 2023.

• R&D expenses decreased to $6.5 million in Q3 2024 from $17 million year-over-year; SG&A increased to $6.5 million from $2.9 million year-over-year.

• Other income, net, increased to $2.7 million in Q3 2024, primarily from higher interest income.

• Accumulated deficit of $132.4 million and total stockholders' equity of $215.3 million as of September 30, 2024.

Outlook and guidance

• Anticipates FDA approval and US commercial launch of LNZ100 in Q4 2025, pending approval.

• SG&A expenses expected to ramp up as launch approaches; sales and marketing spend benchmarked to industry standards.

• Cash position expected to fund operations through commercial launch and to positive operating cash flow.

• R&D expenses expected to decrease further as clinical activities wind down.

• Market exclusivity anticipated via broad IP portfolio and potential new chemical entity status.